Milestone Pharmaceuticals Inc.
MISTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Milestone Pharmaceuticals Inc. (MIST) is listed under Biotechnology. The company carries a $80.7M market cap, placing it firmly in the micro-cap category. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
Market Cap
$80.7M
Beta
1.01
P/E (TTM)
—
P/E (Fwd)
-0.83
EPS (TTM)
$-0.69
EPS (Fwd)
$-0.78
ROE
-35522.6%
ROA
-42.8%
Cash
$170.6M
Total Debt
$141.8M
Free CF
-$41.7M
52W Change
-66.1%
Annual Financials
Cash vs Debt
Where MIST stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, MIST finished 40.15% below its 150-day moving average ($1.32) and 45.52% below its 200-day moving average ($1.45). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MIST overbought or oversold?
At the October 15, 2026 close, MIST's RSI(14) was 49.1, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $170.6M in cash comfortably exceeding the $141.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$41.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -35522.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $5.0M (2022) to $1.5M (2025), a 69% decline worth watching.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing MIST.